Aims Some patients with idiopathic ventricular fibrillation may suffer from the Brugada syndrome. The diagnostic criteria for the Brugada syndrome are uncertain and arbitrarily set. Therefore, we studied the prevalence of the Brugada syndrome using various diagnostic criteria and long-term follow-up in 37 idiopathic ventricular fibrillation patients.
Introduction
Sudden cardiac death frequently results from ventricular tachyarrhythmias in the setting of coronary artery disease. Less prevalent causes of sudden cardiac arrest include cardiomyopathy, congenital heart disease, arrhythmogenic right ventricular dysplasia, the long QT syndrome and the Wolff-Parkinson-White syndrome.
In some patients, the presence of electrolyte disturbances or the use of cardiovascular drugs at the time of the circulatory arrest may be of importance.
In a small number of cases, however, despite extensive clinical evaluation, no underlying structural heart disease can be found. In the past decade, increasing attention has focused on this group of survivors of out-of-hospital cardiac arrest, which is also known as idiopathic ventricular fibrillation [1] [2] [3] [4] . A subset of these patients is characterized by electrocardiographic features consistent with (in)complete right bundle branch block, ST-segment elevation in the precordial leads, and sudden death, as described by Brugada and Brugada [5] . Recently, a prevalence of this syndrome as high as 40% to 60%, has been suggested in idiopathic ventricular fibrillation patients [6] , who have a high risk of recurrence of life-threatening ventricular tachyarrhythmias. The typical ECG morphologies in these patients may change over a period of time, but may be unmasked by administration of a class I antiarrhythmic drug. The syndrome is increasingly recognized [7, 8] and because of a familial occurrence in some patients, a genetic basis has been proposed [5, 9] . Indeed, in some families mutant SCN5A genes encoding the fast sodium channel are involved and electrophysiological studies show altered cardiac sodium channel characteristics [6, 10, 11] . Due to the relative infrequency of idiopathic ventricular fibrillation and the Brugada syndrome, their true prevalence, clinical manifestation and prognosis remain unclear. Furthermore, the diagnostic criteria for the Brugada syndrome are uncertain and arbitrarily set, which could account for the large variation in the percentages of the Brugada syndrome reported so far in the literature. We therefore present data on 37 patients diagnosed with idiopathic ventricular fibrillation and treated at our institute. The data include patient and event characteristics, ECG and electrophysiological data, treatment modalities and long-term follow-up. In addition, we studied the prevalence of the Brugada syndrome using various (sets of) diagnostic criteria.
Methods

Patients
Between October 1985 and March 1999, 37 consecutive patients who survived an out-of-hospital cardiac arrest and were suspected of having idiopathic ventricular fibrillation, were prospectively evaluated after referral to the Arrhythmia Unit of our institute (UMC Utrecht).
Diagnosis
To establish the diagnosis of idiopathic ventricular fibrillation, all known possible causes of sudden cardiac arrest were excluded by thorough clinical evaluation. This was performed in all patients according to a pre-defined protocol. In addition to patient history concerning previous (pre)syncope, palpitations or other cardiac complaints, use of drugs and toxic substances and family history, physical examination, 12-lead ECG, 24-h two-channel Holter monitoring, exercise testing (Bruce protocol) and Valsalva manoeuvre, laboratory tests to exclude acute ischaemia and metabolic or electrolyte disturbances, chest roentgenograms, and echocardiography with wall motion analysis and Doppler screening were performed. Invasive diagnostic measurements included cardiac catheterization with cineangiography of both the left and right ventricle, coronary angiography, nuclear scintigraphic assessment of left ventricular ejection fraction, coronary spasm provocation testing by infusion of ergonovine, and multiple right ventricular endomyocardial biopsies. In the initial patients undergoing thoracotomy for implantation of an implantable cardioverter-defibrillator, additional transmural biopsies were taken from the right and left ventricular walls. Acute myocardial infarction, pre-excitation patterns and the prolonged QT interval were excluded. Measurement of corrected QT intervals was performed according to Bazett's formula.
Baseline electrophysiological study was performed off antiarrhythmic drugs in all patients and included an analysis of the sinus node recovery time and atrioventricular conduction parameters. Programmed electrical stimulation in the high right atrium was performed with the single extrastimulus technique after a basic cycle length of 600 or 430 ms. Inducibility of ventricular tachyarrhythmias was tested at the right ventricular apex and, in case of non-inducibility, also at the right ventricular outflow tract. Programmed electrical stimulation was carried out with a 2 ms pulse width at twice the diastolic threshold current, using up to three extrastimuli during sinus rhythm and ventricular pacing at 600 ms and 430 ms basic drive cycle lengths. In addition, a long-short sequence of extrastimuli was used as described by Denker and colleagues [12] . In case of non-inducibility at a given site, burst stimulation was performed at decreasing cycle lengths until one-to-one ventricular capture was lost. If former techniques did not yield inducibility, the stimulation protocol was repeated (to a maximum of two extrastimuli) under isoproterenol infusion (1 to 4 g . min 1 ), aiming at a heart rate of 120 to 150 during normal sinus rhythm. The end-point of the procedure was completion of the programmed electrical stimulation protocol or reproducible induction of sustained ventricular tachyarrhythmia with or without collapse. Baseline inducibility by programmed electrical stimulation is defined as reproducible induction of ventricular tachycardia (defined as >10 consecutive complexes) or ventricular fibrillation.
Prevalence of the Brugada syndrome
Serial 12-lead ECGs were analysed retrospectively for the presence of (in)complete right bundle branch block, ST-segment elevation in the right precordial leads (V 1 -V 3 ) and their intermittent presence during follow-up. Furthermore, patients were classified according to the maximal amount of ST-segment elevation (mm) observed on their ECG. The effect of drug therapy (class I antiarrhythmic drugs) on ECG morphology was tested in 18 patients (49%), either during chronic oral treatment with flecainide (n=6) or procainamide (n=1) or during a single dose administration of procainamide (1000 mg i.v. at 50 mg . min 1 ) (n=8) or flecainide (2 mg . kg 1 body weight i.v. in 10 min with a maximum of 150 mg) (n=3).
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Initially, treatment with antiarrhythmic drugs was considered a therapeutic option if parameters to assess their efficacy (multiple spontaneous or reproducibly exerciseinduced ventricular tachyarrhythmia episodes and/or baseline inducibility by programmed electrical stimulation) were present. Drug efficacy was evaluated by continuous telemetry, repeated Holter recordings, exercise testing, and programmed electrical stimulation. Antiarrhythmic treatment was not considered efficient in cases of spontaneous recurrence of sustained ventricular tachyarrhythmias, persistent inducibility of ventricular tachyarrhythmia (d5 complexes) by programmed electrical stimulation and/or ocurrence of serious adverse effects of the therapy requiring discontinuation. Programmed electrical stimulation protocols during baseline evaluation and drug testing were similar, including the maximum number of extrastimuli.
In patients with inducible polymorphic ventricular tachycardia or ventricular fibrillation or in the absence of parameters to guide drug therapy, an implantable cardioverter-defibrillator was implanted, either by an epicardial or transvenous approach.
Follow-up
Patients were followed in the outpatient clinic at monthly intervals for the first 3 months after discharge and every 2 to 6 months thereafter. Some patients who did not receive an implantable cardioverter-defibrillator were ultimately referred back to their referring/primary physician, but in most cases follow-up contact was secured; two patients were lost to follow-up. History, physical examination, and a 12-lead ECG were obtained at each visit. Chest roentgenograms and echocardiography were repeated on a yearly basis to exclude or detect the development of features of underlying structural heart disease that might not have been manifested previously.
In patients with an implantable cardioverterdefibrillator, testing of the capacitors of the pulse generator and determination of the charge time were performed every 3 months. Delivery of a shock was counted only when detected at implantable cardioverterdefibrillator interrogation. In later years, the devices were capable of recording the ECG events leading to a discharge. In the other patients, circumstantial evidence was used to classify shock delivery as appropriate or undetermined. Appropriate implantable cardioverterdefibrillator shock is documented shock delivery immediately preceded by syncopal attack, sudden and transient dizziness (pre-syncope), or sudden onset of palpitations. Shocks under other conditions are defined as undetermined.
A major arrhythmic event was defined as either documented ventricular fibrillation, sustained rapid ventricular tachycardia or appropriate implantable cardioverter-defibrillator shock. In addition, major arrhythmic events included prolonged syncope and sudden death without evidence of a non-arrhythmic cause.
Statistical analysis
Comparison of two mean values was performed using the Student's t-test. Proportional differences between groups were analysed using the Fisher's exact test. The Kaplan-Meier method was used for survival curve estimation.
Results
Patient and index episode characteristics
Age, sex and patient characteristics at the index episode are summarized in Table 1 . The study population consisted of 26 men (70%) and 11 women (30%). The mean age at the index event was 35 SD 17 years (range 13 to 73 years); 24 patients (65%) were less than 40 years old. In total, 22 patients (59%) had experienced some previous event, including pre-syncope. At the index episode, in all patients except four, ventricular fibrillation was documented during resuscitation by ambulance personnel. In six patients (16%), the index episode was exercise related, and in five other patients (14%), the event occurred directly after exercise. In some patients, repolarization abnormalities were seen on the initial ECG, but in all patients ischaemia or myocardial infarction was ruled out, as were QT prolongation or electrolyte disturbances. Myocardial biopsies were performed in 32 patients (86%); none of these showed evidence of structural heart disease. Mean left ventricular ejection fraction of the patient group was 60·1% SD 8·5%; three patients had a left ventricular ejection fraction slightly below 50% (49, 45, and 42%), but in all cases overall contractility was good. A family history of sudden cardiac death or unexplained collapse was noticed in only four patients. All patients underwent an electrophysiological study during the initial hospitalization ( Table 2) . Prolongation of the HV (His-ventricle) interval was observed in five patients (14%).
Prevalence of the Brugada syndrome
Retrospectively, nine patients (24%, group I) were classified as potentially having the Brugada syndrome based on the presence of (in)complete right bundle branch block and ST-segment elevation in leads V 1 -V 3 of at least 1 mm. In these patients, a significantly lower heart rate and longer QRS duration were observed on the initial ECG compared to patients without these ECG morphologies (Table 3) . No other differences in baseline characteristics or findings at electrophysiological study were observed. Only three of these patients (8%, group II), showed (in)complete right bundle branch block and at least 2 mm ST-segment elevation on their surface ECG. In six of the nine Brugada syndrome patients (group I) a drug challenge was performed. In two of the six patients challenged, continuous oral treatment with flecainide (n=1) or i.v. administration of procainamide (n=1) resulted in an increase in ST-segment elevation of d2 mm in the right precordial leads (Fig. 1) . In two patients the ECG features were already present prior to the administration of procainamide i.v. (n=2) and did not change significantly. In the other two Brugada patients, the ECG changes did not reappear as a result of continuous oral treatment with flecainide or flecainide i.v., or an increase in ST-segment elevation of only 1 mm was observed. In the 12 patients without signs of the Brugada syndrome, neither continuous oral treatment with flecainide (n=4) or procainamide (n=1), nor administration of procainamide i.v. (n=5) or flecainide i.v. (n=2) resulted in ECG changes. When the intermittent presence of these ECG features and/or their (re)appearance with class I antiarrhythmic drugs were included as criteria, the percentage of the Brugada syndrome was attenuated in both groups I (2/37; 5%) and II (1/37; 3%) ( Table 4) .
Treatment and follow-up
Follow-up of all patients ranged from 6 to 158 months (mean 77 SD 41). Patients 12 and 25 were lost to follow-up. Patient 2 died suddenly while on quinidine; no autopsy was performed and a few years later his sister also died suddenly. No signs of the Brugada syndrome were observed on the ECG in this patient. Patient 9 died of a non-Hodgkin lymphoma. In patient 8, evidence of dilated cardiomyopathy was discovered after she developed signs of congestive heart failure and she underwent 
The Brugada syndrome in idiopathic VF 403
heart transplantation 8 years after the index event. Figure 2 shows Kaplan-Meier survival curves from a recurrent major arrhythmic event according to treatment; no significant difference was found between implantable cardioverter-defibrillator and drug treatment (log rank P=0·26). In total, of the original 37 patients, 16 (43%) had a recurrent episode of either syncope, ventricular tachyarrhythmia or sudden death, varying from one week to a decade after the initial event. In the whole group, three of the 12 patients initially treated pharmacologically with either flecainide, quinidine, or amiodarone, depending on the results of electrophysiological testing of these drugs (Table 2) , had another episode of syncope during follow-up, and were subsequently treated with an implantable cardioverterdefibrillator. Patient 16 was prescribed propranolol because of the occurrence of non-sustained polymorphic ventricular tachycardia during exercise testing. In patient 25, no ventricular tachyarrhythmia was inducible during electrophysiological study, but she refused an implantable cardioverter-defibrillator and was treated with atenolol. In all other patients, either noninducibility at programmed electrical stimulation or insufficient suppression of inducible ventricular tachyarrhythmias was observed and an implantable cardioverter-defibrillator was implanted in these patients. Ten of the 23 patients with an implantable cardioverter-defibrillator had either appropriate shocks or attempted discharges or episodes of (pre)syncope during follow-up. Recurrence rate was independent of 
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age, sex, previous events, family history or findings at baseline electrophysiological study.
Follow-up of Brugada syndrome patients
The mean follow-up of the nine patients with the Brugada syndrome (group I) was 81 SD 53 months (mean 6·8 years) and in two cases more than 12 years. In three of these patients with the Brugada syndrome the ECG pattern disappeared temporarily during follow-up. Only three of all the 16 patients with a recurrent episode of either syncope, ventricular tachyarrhythmias or sudden death, were classified as Brugada syndrome (group I) ( Table 3 ). The recurrence rate was 3/9 (33%) in Brugada patients (group I) and 2/3 (66%) in Brugada patients (group II) (P=ns). A positive drug challenge was not predictive of a recurrent event during follow-up. Patient 1 had a recurrent episode of ventricular fibrillation 2 years after the index event resulting in implantable cardioverter-defibrillator implantation and 9 years later experienced a non-sustained ventricular tachycardia; in patient 22 an episode of non-sustained monomorphic ventricular tachycardia occurred 3 years after the index event. Patient 3 was asymptomatic for 12 years but died suddenly from ventricular fibrillation. One year before death, an aneurysm formed at the right ventricular apex. Arrhythmogenic right ventricular dysplasia was confirmed at autopsy. The other six patients with the Brugada syndrome have remained asymptomatic; four of them have a follow-up of 7 to 12 years. In Fig. 3 , Kaplan-Meier curves for recurrent major arrhythmic events depending on the presence or absence of the Brugada syndrome (group I), show no significant difference in survival between these groups (log rank P=0·20).
Discussion
When an individual survives an out-of-hospital cardiac arrest, much effort is put into unravelling the underlying cardiac disease. The possibility of idiopathic ventricular fibrillation must be considered when most common conditions known to be a possible substrate for the development of life-threatening ventricular tachyarrhythmias are excluded. The difficulty in defining idiopathic ventricular fibrillation is in drawing the line between findings on clinical evaluation that may still be thought of as normal, and those considered abnormal [13] . The results from our single-centre study of 37 idiopathic ventricular fibrillation patients show a relatively young mean age (35 years) at the presenting event (index event), with a high rate of a previous episode of either ventricular fibrillation, ventricular tachycardia, (pre)-syncope or palpitations, but a positive family history of sudden cardiac death or collapse in only a few cases. On the whole, in more than a third of all patients a recurrent major arrhythmic event, ranging from syncope and non-sustained ventricular tachycardia to sudden death, occurred during follow-up. No predictive baseline parameter could be identified. Recurrent events occurred to a similar extent in idiopathic ventricular fibrillation patients with and without the electrocardiographic 'Brugada sign'. In our earlier report we demonstrated an unfavourable outcome of antiarrhythmic treatment in patients with idiopathic ventricular fibrillation who survived an out-of-hospital cardiac arrest [1] . Both favourable and unfavourable outcomes have been reported with class IA antiarrhythmic drug treatment [2, 14] , but a general tendency towards implantable cardioverter-defibrillator treatment is observed [15, 16] . The incidence of the Brugada syndrome among patients with idiopathic ventricular fibrillation remains unclear. In one report a prevalence as high as 40% to 60% has been suggested although criteria were not specified [6] . Criteria used to diagnose the Brugada syndrome are arbitrarily set and often not clearly stated. In this single-centre study we observed a prevalence between 3% and 24%, depending on the criteria used. The magnitude of ST-segment elevation in the right precordial leads in particular, influenced the number of patients diagnosed with the Brugada syndrome. Based on the putative functional nature of the syndrome, i.e. dysfunctioning sodium channels as a result of mutations in the human SCN5A gene [6, 10, 11] , variability of the 
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electrocardiographic characteristics and a significant response to class I antiarrhythmic drugs (i.e. ST-segment elevation of d2 mm) may be of importance. In the absence of a gold standard, the sensitivity and specificity of these criteria remain to be established. Interestingly, in our study, patients with potential Brugada syndrome (group I) had a significantly lower heart rate and a longer QRS duration, suggesting involvement of the conduction system.
Our results indicate the existence of the Brugada syndrome in only a minority of patients with idiopathic ventricular fibrillation. The lower incidence in our study population than previously suggested [6] may result from the fact that in our study patients were only classified as Brugada when at least two diagnostic criteria were present. The results from our single-centre study show a recurrence rate of ventricular tachyarrhythmias in 33% of these patients, with a mean follow-up of more than 6 years and two patients controlled for more than 12 years. However, Brugada et al. reported a recurrence rate of 34% in symptomatic and 27% in asymptomatic patients in a multicentre trial with a mean follow-up of 34 months [17] . We could not confirm the reported high incidence of 'unmasking' or modulation of this ECG pattern by administration of class I antiarrhythmic drugs [18] [19] [20] , although we used an even higher dose than others. However, in some patients the ECG pattern was already present at the time of the drug administration, making interpretation difficult. It is thought that the use of flecainide may be preferable to other class I antiarrhythmic drugs, although preliminary evidence suggests that the sensitivity of the challenge may be only 20% [21] .
In conclusion, we presented results from the largest single-centre prospective study of patients with idiopathic ventricular fibrillation. Depending on the diagnostic criteria used, the Brugada syndrome was observed in 3% to 24% of patients with idiopathic ventricular fibrillation. This variation in prevalence underlines the importance of defining precise diagnostic criteria in these patients. For all idiopathic ventricular fibrillation patients, the recurrence rate of ventricular tachyarrhythmias was substantial during an average follow-up period of more than 6 years, both in patients with and without the Brugada syndrome. The use of implantable cardioverter-defibrillators has reduced mortality rates in these patients and is therefore an important treatment modality in the majority of these patients without an obvious arrhythmogenic substrate. In some patients, antiarrhythmic drug treatment is still an efficient approach, but predicting which patients will respond positively to drug treatment is often hampered by the absence of a reliable parameter to predict a favourable outcome. Although few late manifestations of structural heart disease were observed, the need for careful follow-up evaluation of these patients with regard to the development of cardiac abnormalities remains important for appropriate evaluation of the original diagnosis of both idiopathic ventricular fibrillation as well as the Brugada subcategory. In the absence of unequivocal diagnostic criteria for the Brugada syndrome this entity should be considered as a particular manifestation of idiopathic ventricular fibrillation rather than a different disease.
